⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The cost of GLP-1 medications in India is one of the first and most important questions patients ask — and one of the most confusing to navigate. Prices vary dramatically depending on the drug, dose, pharmacy, city, and whether you are buying through an official channel or a grey market. Imported brand pricing, customs fluctuations, and the absence of most GLP-1 drugs from national insurance schemes make this a landscape every patient needs to understand.
This guide gives you a realistic picture of GLP-1 costs in India as of 2025–2026, compares the options, and shows you legitimate ways to reduce your monthly spend.
Consult your healthcare provider before starting any medication and never change your prescribed medication solely to reduce cost without medical guidance.
Manufactured by: Novo Nordisk
CDSCO status: Approved for Type 2 diabetes
Weight loss use: Off-label (Wegovy is the approved weight-loss version but not yet available in India through standard channels)
Current price range in India:
Ozempic is imported and not manufactured locally. Prices vary significantly by pharmacy and city. Mumbai, Delhi, and Bengaluru generally have lower prices than smaller cities due to better import supply chains.
Manufactured by: Novo Nordisk
CDSCO status: Approved for Type 2 diabetes
Advantage: Oral; no injections required
Current price range in India:
Rybelsus is the most accessible GLP-1 in India because it does not require cold-chain storage for dispensing and is available at more pharmacies. It is generally 15–25% cheaper than equivalent injectable semaglutide doses.
Manufactured by: Eli Lilly
CDSCO status: Approved for Type 2 diabetes (approved 2024)
Dual mechanism: GLP-1 + GIP receptor agonist (often shows greater weight loss than semaglutide)
Current price range in India:
Mounjaro was recently approved in India and is becoming more widely available. Supply is still limited in some cities, particularly tier-2 and tier-3 locations.
Manufactured by: Novo Nordisk
CDSCO status: Approved for Type 2 diabetes
Note: Daily injection (not weekly); older GLP-1 agent; less prescribed now due to weekly alternatives
Current price range in India:
Victoza is the most affordable GLP-1 in India but requires daily injection. It remains widely available and is a genuine option for patients who need a lower-cost entry point.
Manufactured by: Novo Nordisk
India status: Not officially available through standard pharmacy channels as of early 2026
Notes: Some patients obtain through parallel import channels; prices highly variable (₹18,000–₹35,000+ per pen); no patient support programmes available through this route
| Medication | Type | Frequency | Monthly Cost (INR) | Weight Loss Evidence |
|---|---|---|---|---|
| Victoza (liraglutide 1.2mg) | Injectable | Daily | ₹5,500–₹8,000 | Moderate (~5–7% body weight) |
| Rybelsus (semaglutide 7mg) | Oral | Daily | ₹8,000–₹10,000 | Good (~5–8% body weight) |
| Rybelsus (semaglutide 14mg) | Oral | Daily | ₹10,000–₹13,000 | Good (~8–10% body weight) |
| Ozempic (semaglutide 0.5mg) | Injectable | Weekly | ₹9,000–₹12,000 | Good (~8–12%) |
| Ozempic (semaglutide 1mg) | Injectable | Weekly | ₹11,000–₹15,000 | Excellent (~12–15%) |
| Mounjaro (tirzepatide 5mg) | Injectable | Weekly | ₹10,000–₹14,000 | Excellent (~15–18%) |
| Mounjaro (tirzepatide 10mg) | Injectable | Weekly | ₹13,000–₹18,000 | Excellent (~18–22%) |
| Mounjaro (tirzepatide 15mg) | Injectable | Weekly | ₹16,000–₹22,000 | Maximum (~20–25%) |
Prices are approximate and subject to change. Verify current pricing at your local pharmacy or authorised distributor.
At typical therapeutic doses, GLP-1 medications cost:
For most Indian families, even the most affordable option represents a significant financial commitment. Planning for this sustainability is as important as the medical decision.
Many patients are started on higher doses than necessary. Ozempic 0.5mg and Rybelsus 7mg are legitimate therapeutic doses for many patients — not just titration stops. If you are responding well at a lower dose, there is often no clinical need to move higher, saving ₹2,000–₹5,000 per month.
Rybelsus at 7–14mg is meaningfully cheaper than Ozempic and avoids injections. It requires strict dosing protocol (take on empty stomach, wait 30 minutes before eating), but for patients who tolerate it well, the savings are real.
Novo Nordisk India operates patient support programmes for Ozempic and Rybelsus. Your prescribing doctor can refer you. These programmes sometimes offer subsidised pricing, counselling support, and nurse helplines. Ask your doctor directly.
Hospital pharmacies (particularly teaching hospitals and government medical college pharmacies) often dispense at lower margins than private retail pharmacies. In cities like AIIMS Delhi, PGIMER Chandigarh, CMC Vellore, and equivalent institutions, prices can be 10–25% lower.
There is a significant grey market for GLP-1 medications in India — social media groups, unverified online pharmacies, and informal resellers. These channels risk counterfeit medications, improper cold-chain storage, and expired product. Never purchase from unverified sources. The cost savings are not worth the health risk.
Most Indian health insurance policies as of 2025 do not cover outpatient medications for chronic lifestyle conditions. However, some corporate employee health plans and newer individual policies are beginning to include coverage for GLP-1 medications prescribed for Type 2 diabetes. Check your policy documents or call your insurer specifically about Ozempic or Mounjaro.
GLP-1 medications require long-term use for sustained benefit — weight regains when they are stopped. Before starting, have an honest conversation with your doctor about the duration of use you can realistically afford. Some patients do well maintaining on a lower maintenance dose after an initial period at higher doses, reducing cost.
An important practical reality in India: Ozempic, Rybelsus, Mounjaro, and Victoza are CDSCO-approved for Type 2 diabetes management. They are commonly prescribed off-label for weight loss in non-diabetic patients. Insurance coverage, if any, is almost exclusively for the diabetes indication.
If you have Type 2 diabetes, your prescription and documentation should reflect the diabetes indication — this may be the only pathway to any insurance reimbursement.
Stopping medication abruptly due to cost: Discuss financial constraints with your doctor before stopping — there may be dose adjustment options, patient programmes, or therapeutic alternatives.
Buying from Instagram sellers or Telegram groups: Counterfeiting of high-value medications is a real risk. The Ozempic counterfeit problem that affected Western markets in 2023–2024 is beginning to appear in Indian grey markets.
Switching medications without medical guidance: Moving from Ozempic to Mounjaro (or vice versa) requires careful dose calibration. Do not switch self-initiated to save money.
Q: Is there a generic semaglutide available in India? A: As of early 2026, no generic semaglutide or tirzepatide is available in India. The molecules are under patent protection globally. Generic versions are expected in India after 2030 at the earliest.
Q: Why is Ozempic cheaper in some cities? A: Import price variations, distributor margins, and pharmacy competition differ by city. Pharmacies in medical districts of Mumbai, Delhi, and Bengaluru often have tighter margins due to higher competition.
Q: Can I import Ozempic or Wegovy from abroad? A: Importing small quantities for personal use falls in a regulatory grey area in India. Customs sometimes permits it, sometimes confiscates. There is also a cold-chain integrity risk for medications shipped internationally without proper temperature control.
Q: My doctor says I need Mounjaro but I can only afford Rybelsus. What do I do? A: Discuss this directly with your doctor. Rybelsus 14mg is a meaningful therapeutic dose with real clinical evidence. It may not produce the same weight loss as tirzepatide 15mg, but it is a legitimate medical option at lower cost. This is a conversation worth having.
Consult your healthcare provider before starting any medication and have an open conversation about cost and sustainability as part of your treatment planning.
